Accelerate to discover

Back to filter

Related topics

Introducing Cytek Cloud

Cytek Biosciences

Dec 1, 2022

Cytek Cloud is the new digital ecosystem that supports full spectrum flow cytometry research from panel design to data...

See More, Sort More with Cytek Full Spectrum Systems

Cytek Biosciences

Nov 28, 2022

Still wondering whether to join the shift to full spectrum cytometry?  Easily transfer assays from your Cytek Northern...

Demonstrate the value of RareCyte Orion system via web-based Minerva viewer

RareCyte

Nov 25, 2022

The HTA CRC Atlas X dataset contains images and other data being used for construction of an atlas of human colorectal...

ACCELA Educational webinar series: Unlocking Spatial Biology with RareCyte Orion Technology

RareCyte

Nov 16, 2022

Discover full slide, high-plex biomarker quantitation with the all-in-one spatial biology...

Dec 9, 2022

Practical aspects of an imaging study: live in vivo scanning

MOLECUBES

Nov 11, 2022

In this webinar, MOLECUBES will present a live in vivo demonstration, showing the entire workflow from animal...

All inside your incubator: xCELLigence eSight

Agilent technologies

Nov 3, 2022

Multiplex Live cell imaging and real-time biosensor measurement with xCELLigence eSight

Download the newest AVATAR data presented at CAR-TCR

Xcell Biosciences

Oct 21, 2022

Xcell Bio CSO, James Lim, presented new data showcasing improved potency of AVATAR-expanded CAR T cells and highlighted...

Dec 9, 2022

RareCyte Orion system advances Multi-modal digital pathology for colorectal cancer diagnosis

RareCyte

Oct 19, 2022

Precision medicine is critically dependent on better methods for diagnosing and staging disease and predicting drug...

Show all topics (10)

MRI used to determine role of artificial sweeteners in pancreatic cancer disease progression

Jun 13, 2017

Pancreatic cancer has a remarkably high mortality rate, primarily due to late detection of the disease (Siegel et al. 2016). Therefore, efforts to reduce the incidence of pancreatic cancer may provide significant benefit in people at risk of developing the disease. Obese and diabetic individuals are known to have an increased risk of pancreatic cancer (Bardeesy et al. 2002).
Therefore, this study sought to determine whether aspartame or stevia, two commonly used artificial sweeteners, provide benefit in mice with pancreatic cancer. Lead author Dr. James Dooley and colleagues at the University of Leuven in Belgium published their paper entitled, “No Effect of Dietary Aspartame or Stevia on Pancreatic Acinar Carcinoma Development, Growth, or Induced Mortality in a Murine Model,” in Frontiers of Oncology in February of 2017.
The role of artificial sweeteners in cancer risk remains controversial (Tandel 2011), with some studies proposing anti-tumor effects while others purport carcinogenic properties of these chemicals. “With strong links to diabetes, glucose consumption and obesity, pancreatic cancer remains one of the strongest candidates to detect an oncogenic role, either promoting or suppressive, of artificial sweeteners,” the authors begin.
In order to test the potential role of these artificial sweeteners in pancreatic cancer disease progression, the authors allowed mice to drink water with or without aspartame or stevia present. The researchers used a Bruker Biospin 9.4 T Biospec small animal MR scanner to perform magnetic resonance imaging (MRI) in order to locate tumors in the mice and follow their progression over time.

Read more

Scientific paper
Application

Related technologies: Magnetic resonance imaging

Get more info

Miroslav Vecheta

Support specialist

Miroslav

Vecheta

+420 210 323 421

Send Message

Brand profile

Bruker Biospin

Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.

Related products

Multi-purpose high field MRI/MRS research systems, designed for the preclinical imaging and molecular MRI

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey